Recevez les dernières nouvelles sur l'action United Therapeutics avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de UTHR

Dernières nouvelles pour

United Therapeutics

United Therapeutics Corporation - Common Stock

Aperçu

Actualités

Gains

Options

Évaluations des analystes

Transactions internes

Intérêt court

Commerces gouvernementaux

Rapport sur les stocks

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Comments

United Therapeutics Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL